Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03194971 · ClinicalTrials.gov registry record
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
A clinical trial of Glioblastoma, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT03194971 is a study of Glioblastoma that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 20 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03194971, a study of Glioblastoma, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.
Conditions Studied
Interventions
- OTHER Tumor samples from patients treated with TTFields at initial diagnosis.
- DEVICE Tumor samples from patients treated with TTFields at tumor recurrence.
Study Locations (1)
Wisconsin
- Froedtert & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2027-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03194971
The ClinicalTrials.gov registry entry for NCT03194971 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Tumor samples from patients treated with TTFields at initial diagnosis. is the first listed.
NCT03194971 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03194971 about?
NCT03194971 is a clinical study titled "NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy". This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.
What is the current status of trial NCT03194971?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2017-06-01. Estimated completion is 2027-05-31.
What conditions does trial NCT03194971 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT03194971?
The interventions under investigation include: Tumor samples from patients treated with TTFields at initial diagnosis. (OTHER), Tumor samples from patients treated with TTFields at tumor recurrence. (DEVICE).
Who is sponsoring clinical trial NCT03194971?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03194971 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.